ARCELLX, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.64 USD | -2.47% |
|
-1.21% | -7.44% |
| 04-18 | Arcellx Insider Sold Shares Worth $522,260, According to a Recent SEC Filing | MT |
| 04-03 | Arcellx Insider Sold Shares Worth $1,548,887, According to a Recent SEC Filing | MT |
| Sales 2024 * | 86.5M 6.89B | Sales 2025 * | 102M 8.09B | Capitalization | 2.77B 220B |
|---|---|---|---|---|---|
| Net income 2024 * | -106M -8.44B | Net income 2025 * | -122M -9.72B | EV / Sales 2024 * | 24.4 x |
| Net cash position 2024 * | 658M 52.39B | Net cash position 2025 * | 558M 44.47B | EV / Sales 2025 * | 21.7 x |
| P/E ratio 2024 * |
-24.4
x | P/E ratio 2025 * |
-25.6
x | Employees | 130 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.61% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.53% | ||
| 1 week | -1.21% | ||
| Current month | -26.14% | ||
| 1 month | -23.31% | ||
| 3 months | -20.22% | ||
| 6 months | +50.47% | ||
| Current year | -7.44% |
1 week
49.66
55.94
1 month
49.6669.19
Current year
49.6675.10
1 year
30.7475.10
3 years
6.0475.10
5 years
6.0475.10
10 years
6.0475.10
| Managers | Title | Age | Since |
|---|---|---|---|
Rami Elghandour
CEO | Chief Executive Officer | 45 | 21/01/21 |
Michelle Gilson
DFI | Director of Finance/CFO | 32 | 22/05/22 |
David Tice
CTO | Chief Tech/Sci/R&D Officer | 53 | 31/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 31/07/20 |
Ali Behbahani
BRD | Director/Board Member | 47 | 31/01/15 |
Rami Elghandour
CEO | Chief Executive Officer | 45 | 21/01/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 0 M€ | 0.00% | - | |
| 0.01% | 773 M€ | -.--% | - | |
| 0.01% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 51.28 | -1.23% | 158 398 |
| 26/04/24 | 51.92 | +1.05% | 339,688 |
| 25/04/24 | 51.38 | -2.73% | 631,751 |
| 24/04/24 | 52.82 | -2.98% | 312,852 |
| 23/04/24 | 54.44 | +4.69% | 408,988 |
Delayed Quote Nasdaq, April 29, 2024 at 07:32 pm
More quotes
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
51.92
USD
Average target price
80.31
USD
Spread / Average Target
+54.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.44% | 2.77B | |
| +2.43% | 42.75B | |
| +47.70% | 41.61B | |
| +12.06% | 41.34B | |
| -8.83% | 26.59B | |
| +6.65% | 25.49B | |
| -22.87% | 18.12B | |
| +30.41% | 12.24B | |
| -2.05% | 11.76B | |
| +9.21% | 11B |
- Stock Market
- Equities
- ACLX Stock
